Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed By Campath-1H For Previously Treated Relapsed or Refractory Patients With Chronic Lymphocytic Leukemia
| Principal Investigator: | Sanford Kempin, MD |
| Time frame of study: | Ongoing |
| Location of Study: | Beth Israel Medical Center |
| Contact: | Continuum Cancer Research Program |
Summary:
This study aims to evaluate the objective response rate of pentostatin,
cyclophosphamide, and rituximab (PCR) in patients with previously treated
B-cell chronic lymphocytic leukemia (CLL), and to assess the presence
of minimal residual disease (MRD) at the completion of the treatment regimen
and after Campath-1H in patients who achieve a complete remission or nodular
partial remission.
Eligibility and Treatment Plan:
• Age = 18 years
• Previously treated relapsed or refractory Chronic Lymphocytic
Leukemia (CLL)
• Patients must not have had previous CAMPATH-1H therapy prior to
entering the study;
• Women must not be pregnant or breast feeding
Please call for more information.
Copyright © 2008